Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can The Medicines Company Rebound From A Phase III Blow?

This article was originally published in The Pink Sheet Daily

Executive Summary

Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.

You may also be interested in...

TMC Still Optimistic About Cangrelor Approval Despite Negative Opinion

The Medicines Company seemed positive about the prospects for approval of its anti-clotting drug, even though an advisory committee voted against approval just a week ago.

Cangrelor Advisory Cmte. Unsure Whether Plavix Even Needs Replacing

After a brutal panel review, The Medicines Co.’s best chance for its anti-clotting medication may be to create a “better sense of the unmet need” in the perioperative setting when Plavix use must be suspended.

Cangrelor Can’t Escape Its Past At FDA Advisory Committee

The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts